메뉴 건너뛰기




Volumn 47, Issue 4, 2010, Pages 219-226

Efficacy of Setarud (IMOD®), a novel drug with potent anti-toxic stress potential in rat inflammatory bowel disease and comparison with dexamethasone and infliximab

Author keywords

Colitis; Experimental colitis, IMOD ; Inflammatory bowel disease; Oxidative stress; Setarud; TNF antagonist, toxicity

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; DEXAMETHASONE; INFLIXIMAB; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; PEROXIDASE; PLANT EXTRACT; SETARUD; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

EID: 77956132547     PISSN: 03011208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (39)

References (61)
  • 19
    • 77956130717 scopus 로고    scopus 로고
    • USPTO Patent Application 20090208598; EU Patent Application 087825; International Application PCT/EP2006/000820
    • Novitsky YA, Madani H, Gharibdoust F, Farhadi M, Farzamfar B & Mohraz M (2007) USPTO Patent Application 20090208598; EU Patent Application 087825; International Application PCT/EP2006/000820.
    • (2007)
    • Novitsky, Y.A.1    Madani, H.2    Gharibdoust, F.3    Farhadi, M.4    Farzamfar, B.5    Mohraz, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.